Efficacy Analysis of Comparison of CAMS（Chinese Academy of Medical Sciences）-2005 Trial and CAMS-2009 Trial for Pediatric Acute Myeloid Leukemia

Institute of Hematology & Blood Diseases Hospital, China320 enrolled

Overview

The investigators adopted the CAMS（Chinese Academy of Medical Sciences）-2009 trial for pediatric acute myeloid leukemia (AML) patients between 2009 to 2015, in which a risk-stratified strategy and dose-dense intensive chemotherapy were introduced. The outcomes of CAMS-2009 trial were retrospectively analyzed, and compared to the CAMS-2005 trial.

Study Type

OBSERVATIONAL

Enrollment

320

Conditions

Acute Myeloid Leukemia, Pediatric

Interventions

Risk-stratified therapyOTHER

Dose-dense intensive chemotherapy and high dose of Ara-C in the consolidation therapy.

Eligibility

Sex: ALLMin age: 6 MonthsMax age: 16 Years

Medical Language ↔ Plain English

Inclusion Criteria: * newly diagnosed AML Exclusion Criteria: * children with Down's syndrome and acute promyelocytic leukemia (APL)

Locations (1)

InstituteHBDH

Tianjin, Tianjin Municipality, China

Outcomes

Primary Outcomes

overall survival (OS)

overall survival

Time frame: From date of diagnosed until the date of death from any cause, assessed up to 60 months

event-free survival (EFS)

event-free survival

Time frame: From date of diagnosed until the date of first relapse or date of death from any cause, whichever came first, assessed up to 60 months

complete remission (CR)

fewer than 5% blast cells in the bone marrow aspirate and the absence of extramedullary involvement (EMI)

Time frame: through study completion, an average of 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.